Abivax, a biotechnology company, is beginning an extension study concerning ABX464-102, its ulcerative colitis therapy, to evaluate the drug's safety and efficacy.
Here's what you should know:
1. Researchers will recruit patients from Abivax's ongoing proof-of-concept study who are responding to ABX464 for this additional study.
2. The new study is an open label, 12-month follow-up study, which was authorized because ABX464 was found to be safe.
3. Abivax CEO Hartmut Ehrlich said, "We are very pleased with this first authorization for a one-year treatment with ABX464, as it validates the encouraging safety profile of our compound, and we are looking forward to receiving the approvals from additional countries in the coming weeks and months."